It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Alterations in gut microbiota and short chain fatty acids (SCFA) have been reported in autism spectrum disorder (ASD). We analysed the gut microbiota and fecal SCFA in Tunisian autistic children from 4 to 10 years, and results were compared to those obtained from a group of siblings (SIB) and children from the general population (GP). ASD patients presented different gut microbiota profiles compared to SIB and GP, with differences in the levels of Bifidobacterium and Collinsella occurring in younger children (4–7 years) and that tend to be attenuated at older ages (8–10 years). The lower abundance of Bifidobacterium is the key feature of the microbiota composition associated with severe autism. ASD patients presented significantly higher levels of propionic and valeric acids than GP at 4–7 years, but these differences disappeared at 8–10 years. To the best of our knowledge, this is the first study on the gut microbiota profile of Tunisian autistic children using a metataxonomic approach. This exploratory study reveals more pronounced gut microbiota alterations at early than at advanced ages in ASD. Although we did not account for multiple testing, our findings suggest that early interventions might mitigate gut disorders and cognitive and neurodevelopment impairment associated to ASD.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Instituto de Productos Lácteos de Asturias (IPLA-CSIC), Department of Microbiology and Biochemistry of Dairy Products, Villaviciosa, Spain (GRID:grid.419120.f) (ISNI:0000 0004 0388 6652); University of Monastir, Laboratory of Transmissible Diseases and Biologically Active Substances LR99ES27, Faculty of Pharmacy, Monastir, Tunisia (GRID:grid.411838.7) (ISNI:0000 0004 0593 5040)
2 Monastir University Hospital, Unit of Child Psychiatry, Monastir, Tunisia (GRID:grid.411838.7) (ISNI:0000 0004 0593 5040)
3 University of Tunis El Manar, Laboratory of Antimicrobial Resistance LR99ES09, Faculty of Medicine of Tunis, Tunis, Tunisia (GRID:grid.12574.35) (ISNI:0000000122959819)
4 University of Monastir, Laboratory of Transmissible Diseases and Biologically Active Substances LR99ES27, Faculty of Pharmacy, Monastir, Tunisia (GRID:grid.411838.7) (ISNI:0000 0004 0593 5040)
5 Instituto de Productos Lácteos de Asturias (IPLA-CSIC), Department of Microbiology and Biochemistry of Dairy Products, Villaviciosa, Spain (GRID:grid.419120.f) (ISNI:0000 0004 0388 6652); Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Diet, Microbiota, and Health Group, Oviedo, Spain (GRID:grid.511562.4)